DUBLIN–(BUSINESS WIRE)–Feb 19, 2021–
The "TGFb inhibitors – Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com’s offering.
The companies and academics are working to assess challenges and seek opportunities that could influence TGFb inhibitors R&D. The therapies under development are focused on novel approaches for TGFb inhibitors.
In July 2020, Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio.
TGFb inhibitors Emerging Drugs Chapters
This segment of the TGFb inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TGFb inhibitors Emerging Drugs
- Luspatercept – Acceleron Pharma
Luspatercept-aamt is a first-in-class erythroid (red blood cell) maturation agent being developed to treat patients who have serious blood disorders associated with ineffective erythropoiesis. Discovered by scientists at Acceleron, luspatercept-aamt is a recombinant fusion protein that binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling.
TGFb inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different TGFb inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on TGFb inhibitors
There are approx. 10+ key companies which are developing the TGFb inhibitors. The companies which have their TGFb inhibitors drug candidates in the most advanced stage, i.e. phase III include, Luspatercept.
The report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
TGFb inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
TGFb inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TGFb inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TGFb inhibitors drugs.
TGFb inhibitors Report Insights
- TGFb inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
TGFb inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Scenario and Emerging Therapies:
- How many companies are developing TGFb inhibitors drugs?
- How many TGFb inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for TGFb inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the TGFb inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for TGFb inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Acceleron Pharma
- Isarna Therapeutics
- AVID 200
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2fdjhj
View source version on businesswire.com:https://www.businesswire.com/news/home/20210219005190/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 02/19/2021 04:46 AM/DISC: 02/19/2021 04:46 AM